Brief Title
Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom
Official Title
A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Endometrial Cancer in East Anglia, Oxford Trent and West Midlands
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between
genes and the environment in patients with endometrial cancer.
Detailed Description
OBJECTIVES:
- To obtain epidemiological information and biological material on a population-based
series of endometrial cancer cases.
- To define the proportion of endometrial cancer incidence attributable to mutations in
known predisposing genes such as MSH2 and MLH1.
- To determine the risk associated with these predisposing mutations by examining the
cancer risk in relatives of patients who are shown to be carriers.
- To examine the effect of nongenetic risk factors in mutation carriers.
- To determine the pathological and clinical characteristics of endometrial cancers
occurring in mutation carriers as compared with that in noncarriers.
- To establish whether mutations at other loci may predispose to endometrial cancer by
comparing the frequency of alterations in endometrial cancer patients with the
corresponding frequency in cancer-free controls identified through the European
Prospective Investigation of Cancer (EPIC) study.
OUTLINE: This is a multicenter study.
Patients complete an epidemiological questionnaire. The questionnaire will request
identifying information about the patient's first-degree relatives.
Blood samples are collected from patients. DNA is extracted from these blood samples and from
samples collected from cancer-free control participants in MREC-SEARCH-CONTROL as well as
from additional controls through the European Prospective Investigation of Cancer (EPIC)
study (a population based study of diet and health based in Norfolk, East Anglia). DNA
samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes.
In addition to the endometrial cancer patients recruited for this study, patients with
breast, ovarian, prostate, colorectal, bladder, kidney, pancreatic, brain and esophageal
cancer, malignant melanoma, and lymphoma cancer are recruited in the following related
clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-OVARIAN, MREC-SEARCH-PROSTATE,
MREC-SEARCH-COLORECTAL, and MREC-SEARCH-CANCER.
Study Type
Observational
Primary Outcome
Acquisition of epidemiological information and biological material
Condition
Endometrial Cancer
Intervention
polymorphism analysis
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Genetic
Estimated Enrollment
2000
Start Date
February 2008
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of endometrial cancer within the past 5 years
- Identified in any of the following geographic regions of the United Kingdom:
- East Anglia
- Oxford
- Trent
- West Midlands
PATIENT CHARACTERISTICS:
- Identified by the patient's general practitioner as fit to contact for this study
- No serious mental illness or retardation
PRIOR CONCURRENT THERAPY:
- Not specified
Gender
Female
Ages
18 Years - 74 Years
Accepts Healthy Volunteers
No
Contacts
Paul Pharoah, MD, ,
Location Countries
United Kingdom
Location Countries
United Kingdom
Administrative Informations
NCT ID
NCT00758056
Organization ID
CDR0000598877
Secondary IDs
MREC-SEARCH-ENDOMETRIAL
Study Sponsor
Cancer Research UK
Study Sponsor
Paul Pharoah, MD, Study Chair, Cancer Research UK
Verification Date
September 2008